Context Therapeutics Inc.

NASDAQ:CNTX

Biotechnology

Healthcare
$0.69 +2.93%

+$0.02 today

Market cap
$63.67M
Beta
1.61
P/E (TTM)
-1.5
EPS (TTM)
-$0.42
52W Low $0.56High $3.62

Volume 1.71M

Average 1.16M

CNTX Interest Income

Income earned on cash, deposits, and investments held by the company.

Context Therapeutics Inc.NASDAQ: CNTX

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income declines year over year

Q1 FY2026 interest income of $520.14K fell 45.7% year over year, behind the -26.6% change in trailing-twelve-month interest income. Sequentially, it fell 23.8% from the prior quarter. Over 3 fiscal years it compounded at +83.4% a year.

Context

  • Interest income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -45.7% toward the trailing-twelve-month pace of -26.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$520.14K-23.8% QoQ
Last fiscal yearDec 2025
$3.38M+5.6% YoY
LTMMar 2026
$2.94M-26.6% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-45.7%——
1 year+5.6%——
3-year CAGR+83.4%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
3.38M USD
Year-over-year change
+5.6%
4-year CAGR
+1414.4%

Interest Income vs competitors

How CNTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -26.6% is the 4th highest of 10, against a peer median of -41.9%.
  • Over three fiscal years its annual growth of +83.4% compares with a peer median of +19.3%.
CNTX Competitors
Interest Income for CNTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$16.15M USD+417.4%-12.8%—
WHWKWhitehawk Therapeutics IncLTM Mar 2026$6.77M USD+97.1%+37.5%—
IMAImageneBio IncLTM Mar 2026$6.06M USD-9.2%-1.8%—
MGNXMacroGenics, Inc.LTM Mar 2026$5.93M USD-29.4%+26.0%3.8%
CNTXContext Therapeutics Inc.LTM Mar 2026$2.94M USD-26.6%+83.4%—
CNTBConnect Biopharma Holdings LimitedFY2025$2.27M USD-49.1%+13.2%3543.8%
IFRXInflaRx N.V.LTM Mar 2026€1.62M EUR-41.9%+42.8%5520.1%
STTKShattuck Labs, Inc.LTM Mar 2026$779K USD-84.9%+19.3%77.9%
CLNNClene Inc.LTM Mar 2026$189K USD-67.8%—141.0%
OVIDOvid Therapeutics Inc.LTM Mar 2026$0 USD——0.0%
KLRSKalaris Therapeutics IncLTM Mar 2026$0 USD-100.0%——
Peer median (excluding CNTX) —-41.9%+19.3%109.5%

Competitors are the stored peer set for CNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development3.81M7.09M17.78M22.7M31.86M
Selling, General & Admin3.63M7.79M7.29M7.22M7.85M
Operating Expenses10.53M15.38M25.07M29.92M39.7M
Depreciation & Amortization09.27K12.04K10.88K16.25K
EBITDA(7.44M)(14.87M)(23.95M)(26.71M)(36.11M)
EBITDA Margin—————
Operating Income(10.53M)(15.38M)(25.07M)(29.92M)(39.7M)
Operating Margin—————
Interest Income64547.27K1.16M3.2M3.38M
Interest Expense64.24K547.27K000
Other Income / Expenses68.95K545.26K1.11M3.2M3.58M
Income Before Tax(10.46M)(14.84M)(23.96M)(26.73M)(36.12M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(10.46M)(14.84M)(23.96M)(26.73M)(36.12M)
Net Margin—————
EPS (Basic)(3.69)(0.93)(1.50)(0.46)(0.38)
EPS (Diluted)(3.69)(0.93)(1.50)(0.46)(0.38)
Weighted Avg Shares2.83M15.97M15.97M58.42M95.19M
Weighted Avg Shares (Diluted)2.83M15.97M15.97M58.42M95.19M

Context Therapeutics Inc.

NASDAQ:CNTX

Intrinsic Alpha fair value

Locked

Current Price

$0.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.